Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: Results from the ELIAGE and ELICOEUR surveys

International Journal of Cardiology

Volumn 111, Issue 1, 2006, Pages 12-18

  Cournot, Maxime ^a   Cambou, Jean Pierre ^a   Quentzel, Steven ^b   Danchin, Nicolas ^c  

^a INSERM   (France)

^b BRISTOL MYERS SQUIBB   (United States)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Coronary heart disease; Elderly; Non prescription; Observance; Pharmaco epidemiology; Statins; Tolerance

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG INDICATION; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 33746286409     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.06.039     Document Type: Article

References (22)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335 14 (1996) 1001-1009
3. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (2002) 1623-1630
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
5. Danchin N., Grenier O., Ferrieres J., Cantet C., and Cambou J.P. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 88 2 (2002) 159-162
6. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22 7 (2001) 554-572
7. Larsen J., Andersen M., Kragstrup J., and Gram L.F. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol 57 4 (2001) 343-348
8. DeWilde S., Carey I.M., Bremner S.A., Richards N., Hilton S.R., and Cook D.G. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 89 4 (2003) 417-421
9. Ayanian J.Z., Landrum M.B., and McNeil B.J. Use of cholesterol-lowering therapy by elderly adults after myocardial infarction. Arch Intern Med 162 9 (2002) 1013-1019
10. Allen Maycock C.A., Muhlestein J.B., Horne B.D., et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 40 10 (2002) 1777-1785
11. Mungall M.M., and Gaw A. Statin therapy in the elderly. Curr Opin Lipidol 15 4 (2004) 453-457
12. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
13. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24 17 (2003) 1601-1610
14. Fitchett D., Rockwood K., Chan B.T., et al. Canadian cardiovascular society consensus conference 2002: management of heart disease in the elderly patient. Can J Cardiol 20 Suppl A (2004) 7A-16A
15. Aronow W.S. Pharmacologic therapy of lipid disorders in the elderly. Am J Geriatr Cardiol 11 4 (2002) 247-256
16. Vickrey B.G., Rector T.S., Wickstrom S.L., et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33 4 (2002 (Apr)) 901-906
17. Ferrieres J., Cambou J.P., Guéret P., et al. Effect of early initiation of statins on survival in patients with acute myocardial infarction (The USIC 2000 registry). Am J Cardiol 95 4 (2005) 486-489
18. Serruys P.W., Foley D.P., Jackson G., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 20 1 (1999) 58-69
19. Lee C.H., de Feyter P., Serruys P.W., et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart 90 10 (2004) 1156-1161
20. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 4 (2002) 462-467
21. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 341 6 (1999) 410-418
22. Cournot M., Cambou J.P., Ferrieres J., et al. Management of a cardiology patient with polyvascular disease: PRISMA study. Arch Mal Coeur Vaiss 97 9 (2004) 841-848